

Index

- ϵ -optimal rule, 141
- Acemoglu, D., 219
- actual choice behavior, 11
- actualist rationality, 11
- adaptive diversification
- AMR, 127
 - by Bayesian planning, 127
 - implementation of, 127
 - life-threatening disease, 127–129
 - regulatory approval, 129–130
- adaptive minimax regret (AMR), 127, 128
- Administrative Procedure Act (APA), 129
- Afriat, S., 96
- Aikman, D., 41
- Akerlof, G., 60
- Althouse, B., 182
- American Progressive movement, 126
- AMR. *See* adaptive minimax regret (AMR)
- Anderson, R., 186
- Aneja, A., 51
- Angrist, J., 58
- APA. *See* Administrative Procedure Act (APA)
- Armantier, O., 62, 111
- Arrow, K., 25, 29, 151, 198, 200
- as-if optimization, 62–63
- financial accounting, 63–64
- ATEs. *See* average treatment effects (ATEs)
- Atkinson, A., 5
- attributable risk, 56
- average treatment effect (ATE), 69, 71, 137, 139
- axiomatic decision theory, 8–10
- axiomatic theory, 7, 10, 11
- planning, 11–13
- Backhouse, R., A., 31
- Balke, A., 73, 82
- Ball, F., 182
- Bar–Anan, Y., 60
- Barlevy, G., 4
- Barro, R., 32
- basic revealed preference analysis. *See also* revealed-preference analysis
- absence of assumptions, 103
 - labor supply, 104–105
 - preference distribution, restrictions, 105–107
 - proposed tax schedule, 104–105
 - status quo tax policy, 103
 - utilitarian policy evaluation, 107
- Basu, A., 153
- Bayes rules, 140
- Bayesian analysis, 134–135
- Bayesian planning
- mean treatment response, 170
 - x-pox, 121
- BEA. *See* Bureau of Economic Analysis (BEA)
- Becker, N., 182
- before-and-after analysis, 49
- Ben Akiva, M., 114
- Bénabou, R., 60
- benefit–cost analysis, 4, 5
- benefit-risk assessment, 149
- qualitative *vs.* quantitative, 149

- Bentham, J., 25
 Berger, J., 10, 11, 134, 135, 171
 Bergstrom, C., 182
 Bergstrom, T., 182
 Berkson, J., 57
 Berlin, J., 132
 Bhattacharya, J., 74, 75
 Binmore, K., 8, 12, 20
 Black, D., 51
 Blackstone, W., 160
 Blass, A., 114
 Blumstein, A., 48
 Blundell, R., 102
 Boulier, B., 182
 bounded rationality, 29–30
 bounded-variation assumptions, 50, 86–88
 Brief, R., 63
 Briggs, A., 161
 Brito, D., 182, 184
 broken windows policing, 165
 Brown, E. C., xiv
 Brunnermeier, M., 60
 Bureau of Economic Analysis (BEA), 39, 40
 Bureau of Labor Statistics, 39
 Burtis, M., 159

 Campbell, D., 58
 Cao, B., 145, 146
 Caplan, A., 183
 Caplin, A., 60
 carbon-climate response (CCR), 206
 Cassidy, R., 117, 173, 175, 178, 179
 CBO. *See* Congressional Budget Office (CBO)
 CCR. *See* carbon-climate response (CCR)
 Census Bureau, 39
 Cerdeña, J., 161
 CES. *See* Constant-Elasticity-of-Substitution (CES)
 Chavel, C., 160
 Chen, F., 184
 Chernoff, H., 20
 Chipman, J., 25
 choice axioms, 12
 choice behavior, analysis of, 7, 8, 93
 choice set, 14
 choice-based sampling, 56
 Chomsky, N., 55
 classical economic approach, 30
 Climate Model Intercomparison Project Phase 5 (CMIP5), 206
 climate models, 198–199

 CMIP5. *See* Climate Model Intercomparison Project Phase 5 (CMIP5)
 cocaine-control policy, 46–48
 Cochrane system, 131
 Cohen, J., 48
 communicating uncertainty, 213–214
 complete class theorems, 17
 computational model
 details of, 206–208
 findings, 209
 conceptual uncertainty, 43–44
 confrontational proactive policing, 163–167
 Congressional Budget Act of 1974, 38
 Congressional Budget Office (CBO), 38–39
 Connors, A., 74, 75
 consequentialism, 125
 consequentialist decision theory, 7
 choice set, 14
 decision criteria, 15–17
 minimax regret planning, 19–21
 state space, 14
 statistical decision theory, 17–19
 welfare function, 14
 constant treatment response (CTR), 89–90
 Constant-Elasticity-of-Substitution (CES), 101
 conventional certitude, in official economic statistics
 CBO, 38–39
 conceptual uncertainty, 43–44
 economic statistics, 39–40
 permanent statistical uncertainty, 41–43
 statistical agencies, 45
 transitory statistical uncertainty, 40–41
 conventional inference, 24
 convicted juvenile offenders, 122–123
 Cornfield, J., 57
 covariate data, 78–81
 covariate information, value of, 154–156
 COVID-19 pandemic, 145–146, 183
 adoption policy, 219
 epidemiological and macroeconomic modeling, 219
 integrated assessment models, 220
 Response Team of Imperial College London, 217–219
 Cox, D., 88
 CPS. *See* Current Population Survey (CPS)
 Craske, M., 59

- credibility, 11, 12, 14, 30, 35, 43, 47,
 66, 72, 75, 78, 81, 83, 99, 109,
 146, 220
- credible meta-analysis, 91–92
- crime commission, rates of, 159
- frequentist risk assessment, 159
- legal precedents, 159–160
- Cross P., 85
- Croushore, D., 41
- CTR. *See* constant treatment response (CTR)
- Current Population Survey (CPS), 41–43
- Daley, E., 183
- data-invariant rules, 140
- Datta, T., 182
- DBP. *See* diastolic blood pressure (DBP)
- death penalty, 48–50
- Deaton, A., 58
- DeCanio, S., 196, 197
- decision criteria, 15–17
- decision support systems, 214
- decision theory, 6–7. *See also*
 axiomatic decision theory;
 consequentialist decision theory
 axiomatic theorists, 8–10
 consequentialist, 7
 consequentialist structure, 14–21
 institutional separation of research,
 13–14
- deep uncertainty, 22
- DeGroot, M., 134
- Delavande, A., 62, 111, 112
- Delgado, C., 161
- demand-control policy, 46
- Dempster, A., 16
- deontological ethics, 125
- Department of Veteran Affairs (DVA), 79
- hypertension trial, 80
- DerSimonian, R., 91
- deterrent effect
- capital punishment, 50
- death penalty, 48–50
- diagnostic testing and treatment
- ambiguity, 178–180
- two-stage optimization problem,
 174–178
- Diamond, P., xiv
- diastolic blood pressure (DBP), 79
- Dickens, W., 60
- DID. *See* difference-in-difference (DID)
- Dietz, S., 207
- difference-in-difference (DID), 49
- discount-rate uncertainty, 200–201
- disparity aversion, 31
- diversification of treatments. *See also* equal
 treatment of equals
- adaptive diversification, 126–130
- consequentialism, 125
- deontological ethics, 125
- ex ante, 124–125
- ex post equal treatment, 124–125
- Dominguez-Rivera, P., 26
- Dominitz, J., 163
- Dubin, J., 82, 84
- dueling certitudes, in criminal justice
 research
- deterrent effect of death penalty, 48–50
- IDA studies, 46–48
- RAND, 46–48
- RTC, 50–52
- Duggan, M., 51
- Duignan, B., 37
- Durlauf, S., 51
- DVA. *See* Department of Veteran Affairs
 (DVA)
- Dynamic Integrated Climate Economy
 (DICE), 200
- Eames, K., 182, 186
- Earth System Models (ESMs), 206
- effective reproduction rate, 185
- effective vaccination rate, 187
- eGFR. *See* estimated glomerular filtration
 rate (eGFR)
- Eichenbaum, M., 219
- Ellsberg, D., 9, 22
- empirical research
- identification analysis, 21–23
- empirical success (ES) rule, 135, 140
- Environmental Protection Agency, 129
- envy-free allocations of resources, 31
- Epps, D., 160
- equal treatment of equals, 31, 124–126
- ESMs. *See* Earth System Models (ESMs)
- ES rule. *See* empirical success (ES) rule
- estimated glomerular filtration rate
 (eGFR), 161
- ex ante treatment, 124–125
- ex post equal treatment, 124–125
- expression of uncertainty, 61–62
- external validity, 53
- fair allocations of resources, 31
- Faries, M., 143

- federal statistical agencies, 39–40
 Ferguson, T., 134
 financial accounting, 63–64
 Financial Accounting Standards Board (2018), 64
 Fine, P., 182, 186
 Fischhoff, B., 61
 Fisher, F., xiv
 Fixler, D., 40
 Fleiss, J., 56, 57
 Fleurbaey, M., 10
 Foley, D., 31
 Food and Drug Administration Safety and Innovation Act of 2012, 148
 fractional monotone rule, 139
 Francis, P., 184
 Freedman, L., 135
 Friedman, M., 37, 38
Furman v. Georgia case, 48
- GAD. *See* generalized anxiety disorder (GAD)
 Gelbach, J., 159
 generalized anxiety disorder (GAD), 59–60
 GHG emissions. *See* greenhouse gas (GHG) emissions
 Gigerenzer, G., 61
 Gilbert, D., 60, 61
 Gilbert, F., 102
 Giustinelli, P., 112, 113
 Gmeiner, M., 87
 Goldberger, A., 72, 85
 Goldfarb, R., 182
 Gollier C., 60
 Good, I., 170
 greenhouse gas (GHG) emissions, 196
Gregg v. Georgia case, 48
 Gul, F., 11
- Hale, M., 160
 Halloran, E., 182
 Halpern, S., 132
 Hansen, L., 4
 Harsanyi, J.
 initial position arguments of, 27–29
 Hausman, J., 35
 Heal, G., 198, 201
 Heckman, J., 58
 herd immunity threshold (HIT), 186
 heterogeneous decision makers
 conditional choice probabilities, 98–100
 incomplete data, 98–100
 utility theory, 97
 Heymann, D., 182, 186
 Hicks, J., 25
 Hill, A., 182
 HIT. *See* herd immunity threshold (HIT)
 Hoffrage, U., 61
 Holmes, C., 19
 Horowitz, J., 78, 81
 Hsieh, D., 57
 Hudgens, M., 182
 Hurd, M., 62, 111, 112
 Hurwicz, L., 16
 hypertension, trial comparing treatments
 for, 79–81
 hypothesis tests
 medical decisions, 132–133
 Type I error, 132
 Type II error, 132
 hypothetical choice behavior, 11, 12
- IDA. *See* Institute for Defense Analyses (IDA)
 identification analysis, concepts of,
 21–23, 65
 identification region, 66
 identified set, 66
 IIA. *See* independence of irrelevant
 alternatives (IIA)
 illinois unemployment insurance (UI),
 82–83
 Imbens, G., 58
 Immunization Action Coalition, 183
 imprecise probabilities, 112–113
 income-leisure preference, 100
 income tax policy
 basic revealed preference analysis,
 103–105
 labor supply, 100–103
 taxation, 100–103
 incredible certitude
 as-if optimization, 62–64
 in philosophy, 36–38
 psychological rationales for, 59–62
 in religion, 36–38
 statistical agencies, 45
 study planning with, 4–6
 independence of irrelevant alternatives
 (IIA), 20
 individualistic treatment response (ITR), 88
 initial position, 27–29
 Inoue, L., 134
 Institute for Defense Analyses (IDA), 46–48

- Institute of Medicine (IOM), 1, 149
 institutional separation, 13–14
 instrumental variables (IV), 72–75
 integrated assessment (IA), 196
 intention-to-treat, 83–84
 Intergovernmental Panel on Climate Change (IPCC), 199
 internal validity, 53
 International Conference on Harmonisation, 132, 141
 intersection bound, 73
 intolerance of uncertainty (IU), 59–60
 intolerance of uncertainty therapy (IUT), 60
 Intriligator, M., 182, 184
 Ioannidis, J., 133
 IOM. *See* Institute of Medicine (IOM)
 ITR. *See* individualistic treatment response (ITR)
 IU. *See* intolerance of uncertainty (IU)
 IUT. *See* intolerance of uncertainty therapy (IUT)
 IV. *See* instrumental variables (IV)
- Johnson, L. B., 35
 Joint Committee on Taxation (JCT), 38
 juvenile justice system, 69
- Kadane, J., 170
 Kahneman, D., 7, 61
 Kaldor, N., 25
 Kaldor-Hicks efficiency, 26–27
 Kaplan, J., 158–160
 Kaplow, L., 159
 Karlawish, J., 132
 Karlin, S., 139
 Keane, M., 101
 Kessler, R., 59
 Kitagawa, T., 73, 82, 171
 Kleinbölting, H., 61
 Knightian uncertainty, 22
 Knowles, J., 163
 Kobayashi, B., 159
 Koopmans, T., 21
 Kreps, D., 8
 Kunda, Z., 60
 Kuznets, S., 45
- labeling theory, 70
 labor supply, 100–103
 proposed tax schedule, 104–105
 laboratories of democracy, 126
 Lach, S., 114
- Laird, N., 91
 LATE. *See* local average treatment effect (LATE)
 Lazar, N., 133
 Leahy, J., 60
 Li, S., 84, 170
 Litvin, V., 84, 170
 local average treatment effect (LATE), 58
 Lochner, L., 112
 Loeb, M., 182
 long term care (LTC), 113
 Longini, I., 182
 Lott, J., 51
 LTC. *See* long term care (LTC)
 lymph node dissection (lymphadenectomy), 143
 Lyne, O., 182
- MacGregor, D., 61
 macroeconomic planning, 3
 MaCurdy, T., 102
 Manski, C., 2, 11, 13, 15, 18, 20, 22, 30, 31, 36, 40, 42, 43, 48, 50, 52, 55, 57, 58, 62, 63, 65–67, 69, 70, 72, 73, 76–78, 81, 82, 84, 85, 87, 113, 114, 117, 122, 123, 131, 132, 139, 141–143, 145, 154, 162, 163, 165, 167, 170, 171, 173, 175, 178, 179, 196, 197
 Marshall, A., 1
 Materson, B., 79, 81
 Matthews, H., 206
 maximin criterion, 15, 16, 20, 123, 135, 172. *See also* maximin rule
 maximin rule, 136, 140. *See also* maximin criterion
 maximin welfare, 27–29
 May, R., 186
 May, T., 183
 McDermott, R., 183
 McFadden, D., xiv, 57, 114
 mean treatment response
 Bayesian planning, 170
 maximin problem, 168
 MMR planning, 169
 with data from trials
 missing outcome/covariate data, 78–81
 partial compliance, 81–84
 trial-reported findings, 84–88
 with observational data
 counterfactual outcomes, 67–69
 instrumental variables, 72–75

- mean treatment response (cont.)
 - monotone instrumental variables, 75–77
 - monotone treatment response, 77–78
 - recidivism, 69–71
 - sentencing, 69–71
- The Measurement of Social Welfare* (Rothenberg), xiv
- Meghir, C., 101
- Meltzer, D., 153
- meta-analysis, 54–55
- Milner, A., 198, 201
- minimax regret, 20, 63, 118, 119, 126, 140, 180, 194
- minimax regret (MMR) criteria, 15, 16, 62, 119, 120, 122, 124, 127, 135, 179. *See also* minimax-regret rule
- minimax regret (MMR) decisions
 - consequentialist decision theory, 19–21
 - decision rule, 203–204
 - empirical and normative uncertainty, 204–205
 - mean treatment response, 168, 169
 - optimal-control problem, 202–203
 - piecemeal decision making, 179–180
 - SDF, 135–137
 - surveillance/aggressive treatment, 172–173
 - x-pox, 122–123
- minimax regret rule, 140, 141. *See also* minimax regret criterion
- Mirrlees, J., xiv, 26, 27, 31, 100
- missing data, 35, 42, 66, 78–81
- missing outcome, 78–81
- MIV. *See* monotone instrumental variable (MIV)
- MME. *See* multi-model ensemble (MME)
- MMR decisions. *See* minimax regret (MMR) decisions
- model democracy, 199
- Molinari, F., 22, 113
- Mongin, P., 5, 10
- monotone instrumental variable (MIV), 75–77, 87
- monotone treatment response (MTR), 77–78
- monotone treatment rules, 139
- monotone treatment selection (MTS), 76, 77
- Moore, J., 25
- Morgenstern, O., 8, 45
- motivated reasoning, 60–61
- MSLT-II. *See* Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
- MTR. *See* monotone treatment response (MTR)
- MTS. *See* monotone treatment selection (MTS)
- Muermann, A., 60
- Mullahy, J., 31, 154, 162
- Multicenter Selective Lymphadenectomy Trial II (MSLT-II), 143–145
- multi-model ensemble (MME) analysis, 197, 199, 201
- Mushlin, A., 153, 174, 175
- Mustard, D., 51
- Nagin, D., 48, 51, 69, 70, 73, 122, 123, 163, 165, 167
- NASA, 221, 223
- National Academies of Science, Engineering, and Medicine, 210
- National Research Council (2012), 48
- National Research Council (2013), 45
- National Research Council Committee on Data and Research for Policy on Illegal Drugs, 47
- near-optimal treatment choice, 141–142
- new welfare economics, 25
- New York State Ice Co. v. Liebmann*, 126
- nodal observation, 143
- non personalist welfare functions, 30–31
- non-pharmaceutical interventions (NPIs), 217, 218
- non-sampling errors, 42
- Nordhaus, W., 32, 201, 207
- NPIs. *See* non-pharmaceutical interventions (NPIs)
- Nyarko, Y., 111
- O'Donoghue, T., 30
- odds ratio, 56–58
- Office of National Drug Control Policy (ONDCP), 46, 47
- optimal paternalism, in populations, 29–30
- optimal treatment
 - choice between two treatments, 153–154
 - confrontational proactive policing, 163–167
 - covariate information, value of, 154–156
 - crime commission, rates of, 157–160
 - race as covariate risk prediction, 161–162
 - surveillance/aggressive treatment, 156–157
 - utilitarian treatment choice, 167–172
- overconfidence bias, 61

Index

251

- Parker, J., 60
 Parmar, M., 135
 Parmigiani, G., 134
 partial identification, 22–23
 Patel, R., 182
 Paternoster, R., 70
Patient Care under Uncertainty (Manski), xv
 Patient Protection and Affordable Care Act of 2010, 38
 Pearl, J., 73, 82
 Pepper, J., 48, 50, 52, 76, 78, 87
 permanent uncertainty, 41–43
 Persico, N., 163
 personal welfare, 93
 personalism, 31
 Pesendorfer, W., 11
 Pfouts, R., 102
 p-hacking, 133
 Phelps, C., 153, 174, 175
 Phillips, D., 101
 philosophy of science, 37
 piecemeal MMR decision making, 179–180
 Pivato, M., 5, 10
 policy problem, 196–198
 pragmatic welfare, 31–32
 predict behavior, 2
 primacy of internal validity, 59–60
Principles of Economics (Marshall), 1
 proactive policing, 164
 probabilistic expectations, 110–112
The Probability Approach in Econometrics (Haavelmo), 21
 psychological necessity, incredible certitude
 expression of uncertainty, 61–62
 intolerance of uncertainty, 59–60
 motivated reasoning, 60–61
 public health, 56–58
Public Policy in an Uncertain World: Analysis and Decisions (Manski), xv

 quality-adjusted life years (QALYS), 32

 Rabin, M., 30
 race
 confrontational proactive policing, impacts of, 163–167
 as covariate in risk prediction, 161–62
 Ramsey formula, 200
 RAND study, 46–48
 random expected-utility models
 rational expectations assumptions, 109
 returns to schooling of youth, 109–110

 random-effects model, 54
 random utility, 96–100, 108, 112–114
 randomized trials, 58
 Raphael, S. 26
 rational expectations assumptions, 109
 Rawls, J., 27
 initial position arguments of, 27–29
 RCP 8.5. *See* Representative Concentration Pathway (RCP) 8.5
 recidivism, 69–71
 Reconciliation Act of 2010, 38
 reference groups, 90
 regulatory approval, adaptive
 diversification of, 129–130
 Reiersol, O., 72
 Reiss, D., 183
 relative risk, 57
 reliability of the estimates, 42
 religious dogma, 36–38
 representation theorems, 7, 10–11
 Representative Concentration Pathway (RCP) 8.5, 207
 research on planning and actual planning, 13–14
 response-based sampling, 56
 retrospective studies, 56
 revealed preference analysis
 classical consumer
 multiple choice settings, 95–96
 single choice setting, 94–95
 heterogeneous decision makers
 conditional choice probabilities, 98–100
 incomplete data, 98–100
 utility theory, 97
 right-to-carry (RTC), 50–52
 Rivers, D., 82, 84
 Robbins, L., 100, 101
 Robins, J., 82
 robust decisions, 18–19
 Rothenberg, J. xiii, xiv
 RTC. *See* right-to-carry (RTC)
 Rubin, D., 58, 88
 Rubin, H., 139

 sacrificing relevance, certitude
 odds ratio, 56–58
 primacy of internal validity, 58
 public health, 56–58
 randomized trials, 58
 Samuelson, P., 94, 103–105
 Sanstad, A., 196, 197

- Sargent, T., 4
 Savage, L., 8–13, 135, 136
 Schlag, K., 136
 Schotter, A., 62, 111
 Scuffham, P., 182
 SDF. *See* statistical decision function (SDF)
 seasonal adjustment of statistics, 43–44
 Seeskin, Z., 63
 Seidenfeld, T., 170
 semi-monotone treatment response (SMTR), 89–90
 Sen, A., 11, 20, 30, 162
 sentencing, 69–71
 SEW. *See* subjective expected welfare (SEW)
 Shervish, M., 170
 Sheshinski, E., 30, 182, 184
 Silverman, R., 183
 Simon, H., 29, 45, 62
 SIR. *See* susceptible-infectious-removed (SIR)
 SMTR. *See* semi-monotone treatment response (SMTR)
 skepticism, 70, 149
 Smith, A., 4
 Smith, D., 70
 Smith, J., 112
 social cost minimization, 185–186
 social welfare, 2–5
 bounded rationality, 29–30
 maximin welfare, 27–29
 new welfare economics, 25
 non personalist welfare functions, 30–31
 optimal paternalism in populations, 29–30
 pragmatic welfare, 31–32
 utilitarian welfare, 25–27
 x-pox, 123–124
 social choice theory, 5
 specific egalitarianism., 31
 Spencer, B., 63
 Spiegelhalter, D., 135
 Spiegelman, R., 83
 SQF. *See* stop, question, and frisk (SQF)
 Stable Unit Treatment Value Assumption, 88
 Starczak, D., 182
 state of nature, 6
 state space, 6, 14
 statistical decision function (SDF), 17, 18, 24
 Bayes decisions, 134–135
 MMR, 135–137
 STR, 137
 statistical decision theory, 17–19
 statistical discrimination, 151
 statistical imprecision, 23–24
 statistical treatment rule (STR), 137–139
 status quo treatment, 132, 138–141
 Stein, M., 59
 Stern, N., 101, 102, 201
 Stewart, A., 183
 Stiglitz, J., 5
 stop, question, and frisk (SQF), 163, 165
 Stoye, J., 136, 171
 STR. *See* statistical treatment rule (STR)
 subjective data analysis
 hypothetical choice scenarios, 113–114
 imprecise probabilities, 112–113
 probabilistic expectations, 110–112
 subjective expected welfare (SEW), 15–18, 119
 Sugden, R., 12
 Sunstein, C., 30
 supply-control policy, 46
 surveillance/aggressive treatment, 156–157, 172–173
 susceptible-infectious-removed (SIR), 185
 Swan–Ganz catheterization, 74–75
 Swinburne, R., 37
 Tambur, A., 87
 Tamer, E., 22, 65
 tax schedules, 104–105
 taxation, 100–103
 TB. *See* tuberculosis (TB)
 Tetenov, A., 18, 131, 132, 139, 141–143, 145, 171
 Thaler, R., 29
 Tirole, J., 60
 Tobin, J., 31
 Todd, P., 163
 Toxvaerd, F., 184
 Train, K., 114
 transitory uncertainty, 40–41
 treatment choice
 COVID-19 pandemic, 145–146
 mean treatment response, 167–169
 near-optimal treatment choices, 141–142
 observed covariates, 170–171
 with primary and secondary outcomes, 142–145

Index

253

- with sample data, 171–172
- with trial data, 137–141
- treatment response, identification of.
 - See also* mean treatment response
 - concepts and notation, 88–89
 - CTR, 89–90
 - SMTR, 89–90
- Trevino, I., 62, 111
- trial-reported findings, binary categorical
 - variable, 84–85
- bounded-variation assumptions, 86–88
- short trial findings, 85–86
- tuberculosis (TB), 173, 174, 176, 178, 179
- Tukey, J., 55
- Tversky, A., 7, 61
- two-stage optimization problem, 174–175
 - optimization with utilitarian welfare, 175–177
 - threshold risk assessments, 177–178
- Type I error, 18, 132, 133, 136, 142, 147, 150
- Type II error, 18, 132, 133, 136, 142, 147, 150
- UI. *See* unemployment insurance (UI)
- US Census Bureau (2011), 42
- US Food and Drug Administration (FDA)
 - adaptive partial drug approval, 150
 - drug approval process, 147–148
 - rejection of formal decision analysis, 148–150
- uncertainty
 - communication of, 213–214
 - decision making, 22
 - in decision theory, 6–7
 - in empirical research, 21–24
 - in epidemiological models, 2
 - macroeconomic planning, 3
 - in physical-science climate models, 2
 - planning problems, 214–215
 - tractability of decision criteria, 215–216
- unemployment insurance (UI), 82–83
- universal mandate
 - in heterogeneous population
 - optimization problem, 192
 - policy choice without knowledge, 193–194
 - with representative agent
 - optimization problem, 187–188
 - policy choice without knowledge, 188–191
- Urzua, S., 58
- utilitarian social welfare function, 107
- utilitarian welfare, 25–27
- utility models
 - expectations and choice data, 111–112
- utility theory, 97
- vaccination
 - of children and young adults, 183
 - direct effect of, 182
 - of health care workers, 183
 - policy, 181, 184
 - rates, 182, 183
 - policy, 2
 - studied choice of, 184
- Vamos, C., 183
- van der Klaauw, W., 112
- Varian, H., 31, 96
- Venkataramani, A., 31, 154, 162
- Venmans, F., 207
- Von Neumann and Morgenstern (VN-M), 8, 10, 11, 13
- Von Neumann, J., 8
- Vyas, D., 161
- Wald, A., 17, 19, 131, 134
 - ex ante evaluation, 134
 - SDF, 134
 - theory, 17, 18, 23–24
- Walley, P., 16
- Washington Post, 219
- Wasserstein, R., 133
- Watson, J., 19
- welfare economics, 4
 - fundamental theorems of, 4
- welfare function, 14
- welfarism, 30
- wellbeing, 1
- West, P., 182
- Whitchurch, E., 61
- willingness to pay, 26–27
- Wilson, T., 60, 61
- wishful extrapolation
 - experimental treatments to clinical treatments, 53–54
 - meta-analysis, 54–55
 - study populations to patient populations, 52–53
 - systematic review, 54
- Wiswall, M., 112

254

Index

- Wittchen, H., 59
Wolpin, K., 112
Woodbury, S., 83
Wright, J., 44

X-12-ARIMA method, 44
x-pox, 118–120
 Bayesian planning, 121
- maximin planning, 122
minimax regret planning, 122–123
social welfare functions, 123–124
treatments of, 120–121

Zafar, B., 112
Zinman, B., 84, 88
Zissimopoulos, J., 112